- Home
- KTF vs TSHA Comparison
KTF vs TSHA Comparison
Compare KTF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- TSHA
- Stock Information
- Founded
- KTF 1988
- TSHA 2019
- Country
- KTF United States
- TSHA United States
- Employees
- KTF N/A
- TSHA N/A
- Industry
- KTF Finance Companies
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- KTF Finance
- TSHA Health Care
- Exchange
- KTF Nasdaq
- TSHA Nasdaq
- Market Cap
- KTF 366.3M
- TSHA 356.7M
- IPO Year
- KTF N/A
- TSHA 2020
- Fundamental
- Price
- KTF $9.34
- TSHA $1.38
- Analyst Decision
- KTF
- TSHA Strong Buy
- Analyst Count
- KTF 0
- TSHA 8
- Target Price
- KTF N/A
- TSHA $6.63
- AVG Volume (30 Days)
- KTF 103.3K
- TSHA 1.6M
- Earning Date
- KTF 01-01-0001
- TSHA 05-13-2025
- Dividend Yield
- KTF 3.54%
- TSHA N/A
- EPS Growth
- KTF N/A
- TSHA N/A
- EPS
- KTF 0.39
- TSHA N/A
- Revenue
- KTF N/A
- TSHA $8,333,000.00
- Revenue This Year
- KTF N/A
- TSHA N/A
- Revenue Next Year
- KTF N/A
- TSHA N/A
- P/E Ratio
- KTF $23.10
- TSHA N/A
- Revenue Growth
- KTF N/A
- TSHA N/A
- 52 Week Low
- KTF $7.40
- TSHA $1.17
- 52 Week High
- KTF $9.12
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- KTF 35.82
- TSHA 34.93
- Support Level
- KTF $9.27
- TSHA $1.59
- Resistance Level
- KTF $9.43
- TSHA $1.87
- Average True Range (ATR)
- KTF 0.07
- TSHA 0.15
- MACD
- KTF -0.00
- TSHA -0.01
- Stochastic Oscillator
- KTF 28.57
- TSHA 24.36
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.